BeOne Medicines (NASDAQ:ONC) CEO Sells $44,626,172.95 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 145,861 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer directly owned 8,122 shares in the company, valued at approximately $2,484,925.90. This represents a 94.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $317.42 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The firm’s 50-day moving average is $290.21 and its 200 day moving average is $308.93. The stock has a market cap of $34.83 billion, a price-to-earnings ratio of 71.01 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

Several large investors have recently modified their holdings of the company. Cetera Investment Advisers bought a new position in BeOne Medicines in the second quarter valued at about $455,000. Rhumbline Advisers bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $275,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $505,000. Invesco Ltd. bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $68,000. Institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

ONC has been the topic of several recent analyst reports. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Wolfe Research started coverage on BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Finally, Truist Financial boosted their target price on BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.92.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.